全文2202字,阅读约需7分钟,帮我划重点划重点01泰恩康的CKBA软膏Ⅱ期临床已完成全部200例受试者入组,展现出该产品后续开发的巨大潜力。02除此之外,泰恩康今年持续加大研发投入,拥有37项自主研发项目,涵盖了多个治疗领域。03公司核心产品竞争格局良好,如和胃整肠丸、爱廷玖盐酸达泊西汀片和沃丽汀等。04泰恩康计划提交突破性疗法认定申请,以加速CKBA治疗白癜风适应症1类新药的上市进程。05未来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.